Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era.
作者信息
Li Jiakang, Xu Jingyan, Yang Mingyi, Zhou Qing
机构信息
School of Medicine, South China University of Technology, Guangzhou 510006, China.
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
出版信息
Cancer Biol Med. 2022 Jun 9;19(5):569-72. doi: 10.20892/j.issn.2095-3941.2022.0254.
Abstract
摘要
相似文献
1
Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era.免疫时代不可切除的 III 期非小细胞肺癌的治疗革命
Cancer Biol Med. 2022 Jun 9;19(5):569-72. doi: 10.20892/j.issn.2095-3941.2022.0254.
2
Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study.一线纳武利尤单抗联合伊匹木单抗治疗术后复发及不可切除非小细胞肺癌患者的疗效与安全性：一项真实世界回顾性观察研究
Medicina (Kaunas). 2025 May 27;61(6):994. doi: 10.3390/medicina61060994.
3
Therapeutic patterns and outcomes in older patients (aged ≥ 65 years) with stage III inoperable non-small cell lung cancer (NSCLC): An investigational study from the SEER database.老年（年龄≥65岁）Ⅲ期不可切除非小细胞肺癌（NSCLC）患者的治疗模式及结局：一项基于监测、流行病学和最终结果（SEER）数据库的研究。
PLoS One. 2025 Jul 3;20(7):e0327458. doi: 10.1371/journal.pone.0327458. eCollection 2025.
4
Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.同期/序贯免疫检查点抑制与序贯免疫检查点抑制在不可切除的大 III 期非小细胞肺癌患者中治疗的前瞻性观察研究。
J Cancer Res Clin Oncol. 2023 Aug;149(10):7393-7403. doi: 10.1007/s00432-023-04654-w. Epub 2023 Mar 20.
5
6
Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable).对于不适合或拒绝手术（医学上无法手术）的I/II期非小细胞肺癌患者进行根治性放疗。
Cochrane Database Syst Rev. 2001(1):CD002935. doi: 10.1002/14651858.CD002935.
7
Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable).对于不适合或拒绝手术（医学上无法手术）的Ⅰ/Ⅱ期非小细胞肺癌患者进行根治性放疗。
Cochrane Database Syst Rev. 2001(2):CD002935. doi: 10.1002/14651858.CD002935.
8
Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter.不可切除的 III 期非小细胞肺癌患者同步低剂量顺铂与胸部放疗：一项特别参照血红蛋白水平作为预后参数的 II 期试验
J Cancer Res Clin Oncol. 2005 Apr;131(4):261-9. doi: 10.1007/s00432-004-0633-0. Epub 2004 Dec 23.
9
The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitis.对于不可手术的III期非小细胞肺癌，在根治性放化疗后使用度伐鲁单抗巩固治疗对作为肺炎危险因素的治疗相关肺部浸润剂量效应关系的影响。
Transl Lung Cancer Res. 2025 Jun 30;14(6):2074-2088. doi: 10.21037/tlcr-2024-1284. Epub 2025 Jun 26.
10
Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee.靶向治疗联合放疗在不可切除的Ⅰ至Ⅲ期非小细胞肺癌中的新作用：国际肺癌研究协会放疗亚委员会的综述
J Thorac Oncol. 2025 Aug;20(8):1018-1031. doi: 10.1016/j.jtho.2025.05.004. Epub 2025 May 9.
引用本文的文献
1
Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial.增强抗 PD-L1 抗体联合安罗替尼疗效，源于肿瘤微脉管内皮 PD-L1 的下调：一项随机双盲试验。
Cancer Biol Med. 2024 May 29;21(10):951-62. doi: 10.20892/j.issn.2095-3941.2023.0423.
2
Evaluating the Necessity of Adaptive RT and the Role of Deformable Image Registration in Lung Cancer with Different Pathologic Classifications.评估不同病理分类的肺癌中自适应放疗的必要性及可变形图像配准的作用。
Diagnostics (Basel). 2023 Sep 15;13(18):2956. doi: 10.3390/diagnostics13182956.
3
Simultaneous integrated dose reduction intensity-modulated radiotherapy effectively reduces cardiac toxicity in limited-stage small cell lung cancer.同步整合剂量降低强度调制放疗可有效降低局限期小细胞肺癌的心脏毒性。
Cancer Biol Med. 2023 Jun 9;20(6):452-64. doi: 10.20892/j.issn.2095-3941.2022.0326.
本文引用的文献
1
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.COAST 研究：度伐利尤单抗单药或联合奥雷利珠单抗或 Monalizumab 治疗不可切除 III 期非小细胞肺癌的开放标签、II 期、多药物平台研究。
J Clin Oncol. 2022 Oct 10;40(29):3383-3393. doi: 10.1200/JCO.22.00227. Epub 2022 Apr 22.
2
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.舒格利单抗联合同步或序贯放化疗对比安慰剂用于中国局部晚期、不可切除、III 期非小细胞肺癌患者的 GEMSTONE-301 研究：一项随机、双盲、多中心、III 期临床研究的期中分析结果
Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14.
3
Personalized immunotherapy in cancer precision medicine.癌症精准医学中的个性化免疫疗法。
Cancer Biol Med. 2021 Aug 9;18(4):955-65. doi: 10.20892/j.issn.2095-3941.2021.0032.
4
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.帕博利珠单抗联合同步放化疗治疗不可切除的局部晚期 III 期非小细胞肺癌：2 期 KEYNOTE-799 非随机试验
JAMA Oncol. 2021 Jun 4;7(9):1-9. doi: 10.1001/jamaoncol.2021.2301.
5
Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer.同期放化疗治疗 III 期非小细胞肺癌患者的理由。
Br J Cancer. 2020 Dec;123(Suppl 1):10-17. doi: 10.1038/s41416-020-01070-6.
6
Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.了解魁北克一个单一中心不可切除 III 期非小细胞肺癌患者的临床实践和生存结局。
Curr Oncol. 2020 Oct;27(5):e459-e466. doi: 10.3747/co.27.6241. Epub 2020 Oct 1.
7
The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy.年龄对接受放化疗的不可切除局部晚期非小细胞肺癌患者生存结局及放射性肺炎风险的影响。
J Thorac Dis. 2020 Aug;12(8):4347-4356. doi: 10.21037/jtd-20-2137.
8
Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study.无法切除的 III 期非小细胞肺癌的放化疗真实世界结局：SOLUTION 研究。
Cancer Med. 2020 Sep;9(18):6597-6608. doi: 10.1002/cam4.3306. Epub 2020 Jul 30.
9
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
10
Treatment Variation of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients in the Netherlands and Belgium.荷兰和比利时III期非小细胞肺癌患者序贯与同步放化疗的治疗差异
Clin Oncol (R Coll Radiol). 2017 Nov;29(11):e177-e185. doi: 10.1016/j.clon.2017.07.012. Epub 2017 Aug 2.
Zotero 插件